Skip to main content

Table 2 Common treatment-emergent adverse events (most to least prevalent)

From: A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder

Adverse event Quetiapine XR n = 13 (N, %) Placebo n = 13 (N, %)
Somnolencea 10 (77 %) 5 (38 %)
Anxiety 4 (31 %) 0 (0 %)
Constipation 3 (23 %) 1 (8 %)
Dry mouth 3 (23 %) 0 (0 %)
Dizziness 2 (15 %) 3 (23 %)
Restlessness 2 (15 %) 4 (31 %)
Derealizationa 2 (15 %) 0 (0 %)
Insomnia 1 (8 %) 3 (23 %)
Increased appetite 1 (8 %) 2 (15 %)
Leg pain 1 (8 %) 1 (8 %)
Weight loss 1 (8 %) 0 (0 %)
Shakiness 1 (8 %) 0 (0 %)
Muscle aches 0 (0 %) 2 (15 %)
Weight gain 0 (0 %) 1 (8 %)
  1. No significant differences between groups were detected at the p < 0.05 level (Fisher’s exact test)
  2. a3 patients in the XR group discontinued due to side-effects (somnolence or derealization). There were no serious AEs (ones requiring ER or inpatient care)